2型糖尿病合并CKD患者抗促红细胞生成素受体自身抗体的临床与病理意义
本研究纳入112例日本2型糖尿病合并CKD患者,随访平均45个月,用ELISA筛查抗EPOR抗体。23%患者抗体阳性,抗体与低血红蛋白及肾功能下降相关,在活检证实的糖尿病肾病中与间质炎症加重相关;抗体阳性者肾功能下降更常见,且与蛋白尿、低GFR等共同为ESRD的显著危险因素。HK-2细胞实验中含抗体IgG在高糖下上调MCP-1 mRNA。
要点
- 23%的2型糖尿病合并CKD患者检出抗EPOR抗体,与低血红蛋白和肾功能下降相关。
- 活检证实的糖尿病肾病中,抗EPOR抗体与间质炎症增加相关。
- 抗EPOR抗体阳性可能是2型糖尿病进展至ESRD的附加预测因素。
核心结论
- 抗EPOR抗体可能参与2型糖尿病合并CKD患者肾脏病变进展及红细胞生成受损。
- 抗EPOR抗体存在可能是2型糖尿病进展至ESRD的附加预测因素。
研究设计与样本
- 纳入112例日本2型糖尿病合并CKD患者,平均随访45个月,用ELISA筛查血清抗EPOR抗体。
- 对活检证实的糖尿病肾病患者分析抗体与病理间质炎症的关系,并用人肾小管上皮HK-2细胞进行机制实验。
主要发现
- 26例(23%)患者检出抗EPOR抗体,抗体与低血红蛋白浓度及肾功能下降相关。
- 在活检证实的糖尿病肾病中,抗EPOR抗体与间质炎症水平增加相关。
- 抗体阳性者肾功能下降比抗体阴性者更常见,抗体与蛋白尿、低GFR等已知临床参数共同为ESRD的显著危险因素。
- HK-2细胞中,含抗EPOR抗体的IgG组分在高糖条件下上调MCP-1 mRNA表达。
临床怎么用
- 对2型糖尿病合并CKD患者可考虑检测抗EPOR抗体以辅助评估ESRD风险。
- 抗体阳性合并蛋白尿或低GFR者应加强肾功能监测与贫血管理。
局限性
- 样本为日本2型糖尿病合并CKD患者,结果外推需谨慎。
- 抗体阳性与ESRD风险的关联为观察性结果,未证实因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD). METHODS: A total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Sera from these patients were screened for anti-EPOR antibodies using enzyme-linked immunosorbent assays. RESULTS: Anti-EPOR antibodies were detected in 26 patients (23%). Anti-EPOR antibodies were associated with low hemoglobin concentrations and decreased renal function. In patients with biopsy-proven diabetic nephropathy, anti-EPOR antibodies were associated with increased levels of interstitial inflammation. A decrease in renal function was observed more frequently in patients with antibodies than in those without antibodies, and the presence of the antibodies together with well-known clinical parameters, including proteinuria and low glomerular filtration rate, was a significant risk factor for end-stage renal disease. In human tubular epithelial HK-2 cells, IgG fractions containing anti-EPOR antibodies upregulated the expression of monocyte chemoattractant protein-1 mRNA under a high concentration of glucose. CONCLUSION: Anti-EPOR antibodies might be involved in the progression of renal lesions and in the impaired erythropoiesis in type 2 diabetic patients with CKD. Furthermore, the presence of anti-EPOR antibodies may be an additional predictor for end-stage renal disease in type 2 diabetes.
引用
- Hara A, Furuichi K, Koshino A, et al. Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD. Kidney Int Rep. 2017. PMID: 29340323. doi:10.1016/j.ekir.2017.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。